develop position you, our the therapies in has us. that Thus tolerance proven Good which everyone, far, tolerogenic for morning, ImmTOR, immune time responses. platform, and are XXXX year selectively important to thank taking to to leveraging for join mitigate be unwanted we an
on in with trials SEL-XXX we are patients both positive thrilled gout. Phase refractory March, to III data In share chronic of
of observed gout serious benefiting called symptoms, who tophi. potent of pegadricase, consists continue to urate deposits and in as urate SEL-XXX refractory first, reminder, patients a a serum enzyme such pain tissue been that has reduce components: disfiguring to joint have disease As X
than time. the The drugs. administered to second, to is same is of ImmTOR action commonly that at immune proposed to induction drugs are formulation, of as which condition our rapamycin formation And designed tolerance with the is ImmTOR, the immunosuppression antibody other rather system nano-encapsulate that mechanism reduce immune used
we Congress. In late-breaking during presentation our opportunity well the the opinion EULAR European session for or This showcase and key positive data data May, to gout this scientific patients Alliance are was treat and had of who of at Rheumatology of leaders first of physicians limitations the a the Association options. aware current the with to treatment who
the intervention and SEL-XXX the serve response reinforces We immunosuppressants. data, for to based that separate potentially belief were oral our chronic effective could uricase gout refractory by safe traditional once-monthly, a extremely encouraged for without which the as need
XXXX. partner We're of with Sobi, for on half development SEL-XXX track BLA License working the for in on the currently Application compare first U.S. The Biologics our or remains filing focused a filing
for and As Selecta a for reminder, while is Sobi under responsible ImmTOR activities commercial our responsible is in outside regulatory all markets agreement, China, manufacturing. of
entitled on $XXX Sobi up as is in in payments royalties milestone remaining Selecta double-digit tiered receive well million net to as sales. to
million, $XXX of peak refractory and exceed the to significant for SEL-XXX potential SES-XX sales stockholder deliver of for long-term treatment gout believe we potential chronic the the to values. that With has meaningful
program which immune positive platform, validation only ImmTOR tolerance Importantly, the the III platform as SEL-XXX serves represents Phase for with data. a
that balance be to returns for the pipeline that these has would stockholders, required time capital meaningful believe the our SEL-XXX inflection value-creating on firmly our we significant potential generate own. assets While advance to recognize to of our and points beyond we
with and T These programs across combined reduce of investments preexisting anti-AAV AAV cell can further which treatment of protease ImmTOR-IL, development our with mitigation the for combined indications, in of the and next-generation range IgA include immunogenicity MMA, antibodies to for ImmTOR, into As regulatory our IgG plan in initiatives SEL-XXX proprietary pursue a gene for such, Xork IL-X suspend therapy decision which we've be next-generation with and all of combines IgA to selective nephropathy. to the instead corporate SEL-XXX for assets. potential therapeutic licensing a beyond candidate protease undertaken variety and ImmTOR, approaches these
we note, to will with Xork of disease adults. to of To for Astellas's in the advance work development partner, continue late-onset combination Pompe our in with therapy treatment ATXXX, AAV-based Astellas, the
observed As cross-reactivity to a may low with immunity benefit Xork to reminder, unique therapeutic we provide that a AAV. profile in preexisting have patients
will the today of pipeline in without also over and actions maintain our the our capital believe assets continued to preserve dilution the support to SEL-XXX stockholder to been balance would necessary enable of interest term. We that development us have long
turn now results. to call to I'll second that, over financial review Blaine With the quarter
